mNSCLC Video Perspectives

In this video, Erin Schenk, MD, PhD, associate professor of oncology at University of Colorado Anschutz Medical Campus, discusses:

• molecular testing as a “cornerstone of treatment decisions” for patients;
• use of oncogenic drivers, designer therapies as key to making decisions in personalized therapy;
• why detection of mutations, fusions, rearrangements and overamplifications are key in deciding first-line therapy for newly diagnosed patients;
• what is in the pipeline for metastatic NSCLC, including promising clinical trials targeting KRAS G12C mutations; and
• modifications for patients due to COVID-19 and moving forward with therapy, “because oftentimes, our patients can't wait.”